Constraint Methodology for Private Equity Operating Partners and Venture Capital Platform Teams
"The platform team that names the governing structural constraint before the operating plan is approved is not providing better support than the one that deploys the same playbooks against the most visible performance symptom. It is providing a categorically different kind of support — one that changes what every platform function produces by grounding it in the structural cause rather than the situational expression. That is the difference between a platform team that explains why the plan missed and one that documents what the structural intervention produced."
— Lawrence M. Schneider, Founder & CEO, Schneider Axiom Institute — Founder of U.S. Lock Corporation, now owned by The Home Depot
The investment thesis was right. The team is strong. The market opportunity is real.
And the portfolio company is underperforming the model.
Not dramatically — not in a way that has triggered the distress conversation yet. But consistently. The QBR metrics are below the plan. The ARR growth rate is below the comp set. The operational efficiency improvement that was supposed to follow the Series A capital deployment has not materialized at the rate the underwriting assumed. The founder is working hard, communicating well, and managing the business with the genuine capability the diligence process identified. The platform team has deployed the standard support — the go-to-market expertise, the talent advisory, the financial modeling, the operational best practice library.
And the performance gap the investment was designed to close is still there.
You have been in this QBR. Not because the founder is underperforming. Not because the investment thesis was wrong. Because the governing structural constraint limiting the portfolio company's performance was never identified before the operating plan was built around the assumption that the performance gap was a market, team, or execution problem. The constraint has been governing the performance since before the term sheet was signed. It is still governing it now. And the platform team's support — however expert — has been deployed against the symptoms the constraint is producing rather than the structural cause.
The $89 Business Constraint Analysis identifies that constraint — in writing, in 72 hours — before the next operating plan is approved, before the next support deployment is designed, and before another QBR produces the same performance gap with a different quarter's worth of explanation around it.
Four quarters. Four explanations. One governing constraint.
"You have seen this pattern before. Strong team. Real market. Sound thesis. And the portfolio company is underperforming for the fourth consecutive quarter with a different story each time. The story changes every QBR. The governing constraint underneath every story has never changed — and has never been named."
The 12 Realities Every VC Platform Team Recognizes
If that portfolio dynamic sounds familiar, the following twelve realities will feel like your current portfolio.
- A portfolio company is underperforming its ARR growth plan by 30% in the third quarter post-close. The founder's explanation is credible — longer-than-expected enterprise sales cycles, a key hire that took two quarters to fill, a product release that slipped. Every explanation is real. You are reviewing the QBR deck and recognizing that the performance gap predates all three explanations — the ARR trajectory was below plan from the first month post-close, before the sales cycle extended, before the hire was open, before the product slipped. The constraint governing the ARR growth was present at close. It has never been identified as a structural cause rather than a collection of situational explanations.
- A portfolio company's go-to-market platform support deployment produced a playbook that the founder implemented faithfully. The playbook was built on pattern recognition from comparable portfolio companies at the same stage and market. The conversion metrics the playbook was designed to improve have not moved at the rate the comparable companies produced when the same playbook was applied. The playbook is right for the average company at this stage and market. The structural constraint governing this specific company's conversion metrics is specific to this company's positioning, organizational design, or credibility infrastructure — and the generic playbook was not designed to identify it before being deployed against the assumption that the conversion problem was a go-to-market execution problem.
- You have a portfolio company whose NPS scores are exceptional — consistently top decile for the product category, genuine word-of-mouth growth, and a net revenue retention rate that signals strong product-market fit. The ARR growth is below the model. The constraint is financial — the pricing model is capturing a fraction of the value the product is delivering. The platform team's go-to-market support has been aimed at driving more top-of-funnel volume against a financial constraint that is governing the revenue yield of every conversion the top-of-funnel produces. More volume inside a financial constraint produces more revenue at the same below-model revenue per customer. The constraint has never been named.
- A portfolio company is struggling to execute the post-close integration of a strategic acquisition that the investment committee approved as a value creation lever. The integration is running six months behind the operating plan. The founder's explanation is cultural and organizational — the two teams have different ways of working. You are reviewing the integration progress and recognizing that the integration problem is not cultural. It is a structural authority gap — the acquiring company's organizational design has no clear decision-making authority for the cross-functional work the integration requires. The platform team has been providing change management support for a cultural problem that is actually an organizational constraint. The structural cause has never been named.
- You have a portfolio company that has been performing below its ARR benchmark for four consecutive quarters. The board has provided feedback, the platform team has deployed support across go-to-market, product, and operations, and the founder has implemented every recommendation with genuine commitment. You are in the preparation meeting for the fifth consecutive QBR — building the performance narrative, reviewing the metrics, assembling the explanations for why the plan was missed again. And you stop. Because you are looking at four quarters of different explanations — sales cycle in Q1, product delay in Q2, competitive pressure in Q3, hiring gap in Q4 — and recognizing that the explanations have changed every quarter and the performance gap has not. The only constant across four quarters of different situational explanations is a structural constraint that none of them has named. The fifth QBR is being prepared around the sixth situational explanation. The structural cause is still in place.
- A portfolio company's talent density is below the benchmark the investment committee identified as a value creation lever. The platform team's talent advisory support has produced strong hiring — the last four hires are at or above the quality level the operating plan required. The organizational performance has not improved proportionally — because the constraint governing organizational performance is not in the team quality. It is in the decision-making structure above the team — a Leadership constraint that the talent advisory support was never designed to identify before deploying recruiting resources against the assumption that the performance gap was a hiring problem. Better people inside a Leadership constraint produce better people waiting for the same founder decisions at the same decision points.
- You have a portfolio company that is about to initiate a Series B fundraise. The metrics are at the lower boundary of the range the institutional investors in the target round will apply — strong enough to have the conversation, not strong enough to command the terms the model requires. The governing constraint limiting the metrics is identifiable and addressable in the time available before the round closes. It has never been named. The fundraise is being prepared around metrics that a structural constraint is governing — and the narrative around those metrics is being constructed without knowing whether the constraint can be addressed before the close or needs to be reflected in the round structure.
- A portfolio company's customer acquisition cost has been increasing for three consecutive quarters despite the platform team's go-to-market optimization support. The CAC increase is being attributed to market saturation and increased competitive intensity — both of which are contributing. You are reviewing the cohort data and recognizing that the CAC increase correlates with the company's expansion into a second customer segment that was not in the original go-to-market motion. The structural constraint is strategic — the company is distributing its go-to-market attention and budget across two segments simultaneously without enough concentration in either to maintain the CAC efficiency the model requires. The competitive intensity is real. The strategic constraint is governing the CAC pattern. The constraint has never been named.
- You are preparing the portfolio review for the LP meeting. The performance narrative for three of your portfolio companies requires an explanation for why the QBR metrics are below the operating plan assumptions the LPs approved at the investment committee. The explanations are accurate — market conditions, execution challenges, competitive dynamics. None of them name a structural constraint in the business that the platform team identified, addressed, and documented as a value creation intervention. The LP narrative for those three companies is a situational explanation rather than a structural story. The difference between a situational explanation and a structural story is the difference between a portfolio company that is behind plan because the market was hard — and one that was behind plan because a structural constraint was governing the performance, the platform team named it, and the performance improved when the constraint was addressed.
- Your platform team has deployed support across go-to-market, talent, operations, and finance for the portfolio. The support quality is high — the expertise is genuine and the playbooks are built on real pattern recognition from comparable companies. The portfolio companies that are performing above plan are disproportionately the ones whose governing structural constraint was identified early and addressed before the support was deployed against the symptoms it was producing. The portfolio companies that are performing below plan are disproportionately the ones whose governing structural constraint has never been named — and whose platform support has been deployed against a collection of situational explanations rather than a named structural cause.
- A portfolio company is approaching the end of its runway with ARR below the level required for the next institutional round. The board is evaluating bridge options and strategic alternatives. You are reviewing the company's operating history and recognizing a pattern — every quarter of the company's post-close operating history shows platform support deployed against the most visible performance problem of that quarter. No quarter shows a systematic structural diagnosis of the governing constraint. The constraint that is now producing the runway crisis was identifiable before the Series A closed. It has been governing the performance since. The platform team has been managing the symptoms for four years.
- You want your platform team to be known for one specific capability that no other VC platform in the market is providing — the systematic identification of the governing structural constraint in every portfolio company before the operating plan is approved and the support is deployed against it. That capability is not a platform feature. It is the difference between a platform team that provides excellent support inside performance gaps — and one that changes what the support produces by naming the structural cause before the support is aimed at the symptom.
What the Platform Team's Support Is Actually Producing — and What Changes When the Constraint Is Named First
Every platform team function — go-to-market support, talent advisory, operational excellence, financial modeling, product strategy — is designed to improve portfolio company performance by deploying pattern recognition and expertise against the performance gaps the operating plan identifies.
The gap that every platform team encounters is not in the quality of the support. It is in the connection between the support and the specific structural constraint governing the performance gap the support is deployed to address. A go-to-market playbook deployed against a company whose governing constraint is financial will produce excellent top-of-funnel execution against a revenue yield problem the go-to-market motion was never designed to address. A talent advisory engagement deployed against a company whose governing constraint is organizational will produce excellent hiring against a decision authority problem that better people will not resolve.
The platform support is right for the average portfolio company in the performance category the support is designed to address. The structural constraint is specific to this company — and until it is named, the support is aimed at the most visible expression of the constraint rather than its structural cause.
The $89 Business Constraint Analysis closes that diagnostic gap at the individual portfolio company level. Each founding team completes the diagnostic before the operating plan is approved and the support deployment is designed. Within 72 hours they receive a written report naming the specific governing constraint across all seven categories. The platform team receives an aggregated portfolio summary showing the distribution of constraints across the portfolio — which constraint categories are most prevalent, which portfolio segments are most commonly governed by which constraint types, and what the structural data suggests about the support deployment priorities that will produce the highest-leverage performance improvement across the portfolio.
That aggregated summary changes two things simultaneously. It gives the platform team something it has never had — a systematic structural basis for every support deployment decision, every operating plan approval, and every QBR performance conversation. And it gives every portfolio company something no platform team has ever provided — a written structural finding that names the governing constraint before the operating plan is built around the assumption that the performance gap is a market, team, or execution problem.
The Seven Constraint Categories — Through the Lens of a VC Portfolio Company
Every governing structural constraint limiting a portfolio company's performance lives in one of seven categories. Until the specific category is named before the operating plan is approved, the platform support is deployed against the performance problem as described rather than the structural cause. Here is what each constraint looks like from inside a venture capital portfolio relationship.
A Market constraint is what the portfolio company is dealing with when the sales motion is strong, the team is executing well, and the ARR growth is below the model. The constraint is in the market position — the company is competing in the wrong segment or leading with the wrong value proposition at the revenue per customer level the model requires. The platform's go-to-market support is producing better execution of a market strategy the market constraint is governing. More pipeline, better conversion, stronger customer success — inside a market constraint — produces better execution of the wrong strategic direction. The support is aimed at the execution. The market constraint is governing the commercial outcome.
An Operational constraint is what the portfolio company is dealing with when the demand is real and the delivery is below the quality or velocity the retention model requires. The constraint is in how the company delivers at the scale the ARR growth demands — a structural bottleneck that the operational excellence support is working around rather than through. More process documentation, better tooling, stronger operations hiring — inside an operational constraint — produces better management of a structural bottleneck that the support was never designed to identify and remove. The support is improving the operation. The operational constraint is governing what the improved operation can produce in retention and revenue.
A Financial constraint is what the portfolio company is dealing with when the product is strong, the NPS is high, and the revenue growth is below the model. The constraint is in the financial structure of how the company captures the value it delivers — the pricing model, the packaging, or the contract structure that is producing a revenue ceiling that the product's genuine value delivery does not reflect. Better customer success inside a financial constraint produces better relationships at the same below-model revenue per customer. The support is improving the engagement. The financial constraint is governing the revenue yield.
An Organizational constraint is what the portfolio company is dealing with when the team is strong and the organizational execution is below what the team quality should be producing. The constraint is in how decision-making authority is distributed across the organizational structure — the gaps and bottlenecks that are governing execution velocity regardless of the talent density the platform's hiring support has produced. Better talent inside an organizational constraint produces better people waiting for the same decisions at the same decision points. The support has improved the team. The organizational constraint is governing what the better team can produce in execution speed and quality.
A Strategic constraint is what the portfolio company is dealing with when the team is executing across multiple initiatives and producing below-model results across all of them. The constraint is in how the company's leadership attention is allocated across its strategic priorities — too many directions simultaneously for any one of them to build the compounding momentum the ARR growth model requires. Better priority frameworks inside a strategic constraint produce clearer descriptions of the wrong allocation pattern. The support is sharpening the strategy. The strategic constraint is governing whether the strategy produces compounding momentum or distributed effort.
A Leadership constraint is what the portfolio company is dealing with when the organizational velocity is below the benchmark and the team quality is not the explanation. The constraint is in the decision-making structure at the founder level — the bottleneck that is governing the speed and direction of the organization below it regardless of the talent density, the process quality, or the go-to-market strength the platform's support has produced. More capable teams inside a Leadership constraint produce more capable people waiting for the same founder decisions at the same decision points. The support has built the team. The Leadership constraint is governing what the team can produce in organizational velocity.
A Credibility constraint is what the portfolio company is dealing with when the enterprise sales motion is strong and the conversion rate is below the model. The constraint is in the market's authority assessment of the company — the enterprise buyer requires a credibility signal that the company has not yet established at the investment level the sales motion is pursuing. More enterprise pipeline inside a Credibility constraint produces more late-stage deals stalling at the same procurement objection. The support is improving the sales motion. The credibility constraint is governing the conversion.
What the Portfolio Support Looks Like When the Diagnostic Comes First
Most platform support deployments begin with the performance gap — the QBR metric that is below plan, the ARR growth rate that is below the comp set, the operational efficiency that is below the underwriting assumption. The support is designed around the most visible performance gap. The structural constraint governing that gap emerges — if it emerges — through the support engagement as the platform team works through the performance problem with the founder.
Here is what the support deployment looks like when the $89 Business Constraint Analysis comes before the operating plan is approved.
The founding team completes the diagnostic before the post-close operating plan is finalized. Each person invests 30 minutes. Within 72 hours they each have a written report naming the specific governing constraint. The platform team receives an aggregated summary showing the distribution of constraints across the founding team — which categories are most prevalent and where the founding team's description of the performance gap diverges from the structural finding.
That divergence is the most valuable input the platform team can have before the operating plan is approved. Where the founding team believes the performance gap lives versus where the diagnostic finds the structural cause — that gap tells the platform team whether the operating plan is being built around the structural cause or the most visible symptom. If the operating plan is aimed at a go-to-market problem and the diagnostic identifies a financial constraint — the operating plan is redesigned before the support is deployed against the wrong problem. If the operating plan is aimed at a talent problem and the diagnostic identifies a Leadership constraint — the support is redirected to the structural cause before more hiring resources are deployed against the symptom.
The QBR is different. The founder arrives with a named structural constraint, a documented intervention, and a measurable performance improvement — rather than a collection of situational explanations for why the plan was missed. The board conversation is different. The LP narrative is different. And the platform team that provided the structural finding before the operating plan was approved is not competing on playbook quality and domain expertise alone — it is competing on something no other platform in the portfolio's market is providing.
Which SAI Credential Is Right for Your Platform Team
SAI credentials are standalone programs. No credential is a prerequisite for another. The right choice depends on how the diagnostic methodology will be deployed within the platform team's portfolio support model.
FDC — Foundational Diagnostic Credential — $697
Best for: Portfolio company founders and leadership team members who want to own the permanent internal capability to identify and diagnose governing constraints in their own organization — so the diagnostic skill is applied to every operating plan, hiring decision, and capital deployment decision the company makes as it scales.
Application: Most valuable as a recommendation to portfolio company founders whose diagnostic finding reveals a governing constraint they want to address with systematic diagnostic capability permanently installed in how the organization makes operating decisions — rather than a one-time finding that informs the current operating plan cycle.
Explore the FDC in Detail →CAS — Certified Axiom Strategist — $1,997
Best for: Platform team members, portfolio operations professionals, and value creation team leads who want a verifiable systematic diagnostic methodology to deploy as the foundation step of every post-close support engagement — ensuring that every operating plan is built around the structural cause of the performance gap rather than its most visible expression.
Application: Deploy the $89 analysis as the standard pre-operating-plan diagnostic for every portfolio company. Use the aggregated portfolio summary to calibrate support deployment priorities across the portfolio. Change what every platform support function produces by grounding it in named structural constraints rather than observed performance gaps. Earn referral commission on every analysis and credential enrollment that flows through the practice. Most selected by VC Platform Team Members.
Explore the CAS in Detail →CAE — Certified Axiom Executive — $4,997
Best for: Senior platform team leaders, managing directors of portfolio operations, and general partners whose value creation work is conducted at the board and governance level — where the constraint diagnostic needs to hold authority in investment committee, board, and LP conversations about portfolio performance.
Application: Enterprise-level constraint diagnostic frameworks for portfolio support engagements where the structural constraint analysis is presented at the board level — and where the diagnostic finding needs to hold authority in the governance conversation that precedes the operating plan approval and the capital deployment decision. Priority placement in the SAI Practitioner Referral Network. Application required — reviewed personally by Lawrence M. Schneider.
Explore the CAE in Detail →Compare All Programs Side by Side →
The Portfolio Deployment Structure — What SAI Looks Like Across a VC Portfolio
SAI works with venture capital platform teams through a structured portfolio deployment model designed around three objectives — portfolio company value, platform team intelligence, and LP narrative.
Portfolio company value — Every portfolio company founding team that completes the $89 analysis before the operating plan is approved receives individual written constraint findings within 72 hours. The findings are delivered as a named platform support component — the pre-operating-plan structural diagnostic that every founding team completes before the first post-close QBR and brings to every support engagement that follows.
Platform team intelligence — The platform team receives an aggregated portfolio summary showing which constraint categories are most prevalent across the portfolio, which portfolio segments are most commonly governed by which constraint types, and what the structural data suggests about the support deployment priorities that will produce the highest-leverage performance improvement across the portfolio. This summary is the most specific and most actionable portfolio intelligence any platform team has ever had before the post-close support is designed.
LP narrative — The platform team that deploys the SAI diagnostic as a standard portfolio component is the team whose QBR performance narratives include structural constraint findings, documented interventions, and measurable performance improvements — rather than situational explanations for why the plan was missed. That narrative changes what the LP meeting conversation is about — and what the platform's value creation track record looks like across the portfolio.
Contact SAI directly at info@schneideraxiom.org to initiate a portfolio deployment conversation. Lawrence M. Schneider reviews every venture capital partnership inquiry personally.
"I have been the portfolio company founder in that QBR — presenting metrics that were below plan with explanations that were accurate and incomplete. The sales cycle was long. The key hire took time. The product release slipped. Every explanation was true. None of them named the structural constraint that was governing the performance gap before any of those situations developed. I built the SAI methodology because naming the constraint before the operating plan is approved is the intervention that changes what the plan can produce — not the situational narrative that explains why it did not."
— Lawrence M. Schneider, Founder and CEO, Schneider Axiom Institute — Founder of U.S. Lock Corporation, now owned by The Home Depot
Lawrence M. Schneider spent more than 50 years on the operating side of institutional capital relationships — the founder and CEO whose performance gaps were governed by structural constraints that the investor's support addressed at the symptom level and never at the cause. He built the SAI methodology from that direct operating experience. The platform team that deploys it as a standard portfolio component gives every portfolio company something no platform in the market is currently providing — a written structural finding that names the governing constraint before the operating plan is built around the assumption that the performance gap is a market, team, or execution problem.
Seven Documented Outcomes — All Seven Constraint Categories Represented
Market Category
Named a market constraint in a B2B SaaS portfolio company whose platform team had deployed an enterprise go-to-market playbook post-close. The ARR growth was 60% of plan three quarters post-close. The platform team's explanation was sales execution and pipeline quality. The diagnostic identified that the constraint was not in the execution — the company was competing in a segment where its product's differentiation was not relevant to the primary buying criterion. The go-to-market playbook was optimizing sales execution in the wrong segment. Result: After repositioning to the segment where the product's differentiation was the primary buying criterion, ARR growth accelerated to 140% of plan within two quarters. The platform team redesigned the go-to-market support around the repositioned segment. The ARR trajectory entered the Series B fundraise above the benchmark the institutional investors were applying.
Operational Category
Identified an operational constraint in a marketplace portfolio company whose platform team had been providing supply-side growth and operations support. The marketplace's GMV growth was below plan because the supply quality was declining as supply volume increased — a pattern the platform team had attributed to onboarding process quality. The diagnostic identified a structural bottleneck in the supply verification sequence — a manual review step that was creating a quality inconsistency at scale that the onboarding process improvement was working around rather than through. Result: After restructuring the verification sequence, supply quality metrics improved materially within 45 days and GMV growth accelerated to plan within one quarter. The onboarding process improvement the platform team had implemented produced its full impact immediately once the operational constraint governing the quality at scale was removed.
Financial Category
Named a financial constraint in a vertical SaaS portfolio company whose platform team had been deploying customer success and expansion revenue support. The net revenue retention was at 108% — strong but below the 120% the model required for the Series B round. The platform team's expansion playbook was producing upsell conversations, but below-model upsell conversion. The diagnostic identified a pricing structure constraint — the product's packaging did not create a natural expansion trigger at the usage level where the upsell conversation was being initiated. Result: After restructuring the packaging to create a natural expansion gate at the usage threshold where customers were already engaging, net revenue retention improved to 124% within two quarters. The customer success and expansion support produced the NRR improvement the Series B required once the financial constraint governing the expansion architecture was addressed.
Organizational Category
Identified an organizational constraint in a growth-stage portfolio company whose platform team had been providing talent advisory and organizational design support. The company had made four strong hires in the post-close period. The organizational execution velocity had not improved proportionally — engineering was shipping below the roadmap timeline and commercial was missing pipeline targets despite the talent additions. The diagnostic identified a structural authority gap — the CTO and CRO both required CEO involvement for decisions that should have been within their authority, creating a decision queue that was governing velocity across both functions. Result: After restructuring the decision authority framework — distributing architecture and commercial decisions to the functional leads within defined parameters — engineering velocity improved 55% and commercial pipeline attainment improved to 94% within 60 days. The talent advisory the platform team had been providing produced its full organizational impact immediately once the authority constraint was removed.
Strategic Category
Named a strategic constraint in a Series B portfolio company whose platform team had been providing go-to-market and product strategy support across three simultaneous market segments. The company was executing well in all three segments — the sales team was skilled, the product was genuinely competitive, and the customer success was strong. ARR growth was below plan across all three because no single segment had enough concentrated go-to-market investment to reach the density and referral network that the ARR growth model in each segment required. Result: After concentrating the full go-to-market investment on the highest-margin segment for two quarters, that segment reached its ARR milestone within the timeline the model projected. The platform team's go-to-market support produced the ARR growth the model required once the strategic constraint governing the attention distribution was named and addressed.
Leadership Category
Identified a Leadership constraint in a founder-led portfolio company whose platform team had been providing operational excellence and process improvement support. The company's operational velocity was below benchmark despite strong process quality and a capable team. The board had attributed the velocity problem to team capability. The diagnostic identified a Leadership constraint — the founder was the approving authority for every customer commitment, every significant product decision, and every non-standard commercial term. The operations process improvements were producing better-documented processes that still required the same founder approval at the same decision points. Result: After restructuring the decision authority to distribute customer commitments and commercial approvals to the commercial team within defined parameters, operational velocity improved to benchmark within 30 days. The founder described the decision authority restructuring as the most commercially significant operational change since the company's founding.
Credibility Category
Named a Credibility constraint in an enterprise software portfolio company whose platform team had been providing enterprise go-to-market support. The sales team was strong, the product was differentiated, and the pipeline was at plan. The enterprise conversion rate was below the model — late-stage deals were stalling at the procurement and security review stage at a rate that the go-to-market support's objection handling training was not reducing. The diagnostic identified a Credibility constraint — the company did not yet have the SOC 2 Type II certification, the enterprise reference customers, or the procurement process documentation that the target buyer's security and procurement teams required before authorizing contracts at the deal size the model required. Result: After investing six weeks in the credibility infrastructure — SOC 2 certification, two anchor reference customers, and a standardized procurement response package — the late-stage conversion rate improved by 34% within one quarter. The enterprise go-to-market support produced the conversion improvement the model required once the credibility constraint governing the procurement approval was addressed.
A Note on the Platform Functions Your Team Already Deploys
Your platform team's go-to-market expertise, talent advisory, operational excellence support, and financial modeling capability represent accumulated pattern recognition from portfolio companies that have navigated the same performance gaps at the same stages. The SAI diagnostic does not replace any of those functions. It identifies the specific structural constraint governing each portfolio company's performance gap — which changes what each platform function is deployed against.
A go-to-market playbook deployed against a portfolio company whose diagnostic identifies a financial constraint is deployed against the revenue yield problem — not the top-of-funnel problem the playbook was designed to address. A talent advisory engagement deployed against a portfolio company whose diagnostic identifies an organizational constraint is deployed against the decision authority structure — not the hiring quality problem the talent advisory was designed to solve. The platform expertise is the same. The constraint finding changes what it is aimed at — and that change is what produces the performance improvement the operating plan required rather than the incremental improvement the symptom-level support was producing.
Who This Is Not For
The SAI portfolio deployment is not the right fit for every venture capital platform team, and we are direct about that.
It is not the right fit if the platform team's primary function is LP relations, fund administration, or deal origination rather than active portfolio company performance support. The SAI diagnostic produces the most value for platform teams whose primary mandate is improving portfolio company operating performance through hands-on support engagement with founding teams.
It is not the right fit for portfolio companies in the first 90 days post-close whose primary constraint is founder bandwidth and operational setup rather than a structural performance constraint that has had time to develop and express itself in identifiable performance patterns. The diagnostic produces its most specific and actionable results for companies that have been operating long enough to have a QBR data history that reflects an identifiable structural pattern.
It is not the right fit if the platform team's founding team counterparts are not willing to invest 30 minutes completing a written structural self-assessment as part of the post-close support onboarding. A founding team that is not willing to engage seriously with a structural diagnostic before the operating plan is approved is a founding team whose operating plan will be built around the same performance assumptions it would have been built around without the diagnostic.
If your platform team is deploying support against performance gaps that keep presenting in different forms across consecutive QBR cycles — this was built for your practice.
If You Are Still Deciding
"I am not sure the $89 analysis will identify anything our diligence process or post-close onboarding has not already revealed."
Your diligence process identifies what the founding team and the market data reveal about the performance opportunity and the execution risk. Your post-close onboarding identifies the operating priorities the founding team has defined for the first 90 days. The $89 analysis identifies the specific structural constraint governing the performance gap the operating plan is designed to close — which frequently differs from what the diligence or the onboarding revealed. When they differ the diagnostic finding is the more important operating plan input — because it tells the platform team whether the support is being designed to address the structural cause or the most visible symptom. An operating plan aimed at a structural constraint produces performance improvement. An operating plan aimed at the symptom produces better management of a constraint that is still governing the performance.
"I am not sure the CAS will change anything meaningful about our portfolio company performance outcomes."
It changes one specific and consequential thing — every operating plan is approved with the knowledge of what structural constraint the plan is designed to address. A plan designed around a confirmed structural cause produces the performance improvement the operating model projected. A plan designed around the most visible performance symptom produces better symptom management — and a QBR narrative that explains why the plan missed rather than demonstrating what the structural intervention produced. That difference is the difference between a platform team whose value creation narrative is structural and documented — and one whose value creation narrative is situational and explanatory.
"I want to understand the methodology before deploying it across the portfolio."
Complete the $89 analysis on your own organization before deploying it with a single portfolio company. If within 72 hours of report delivery the report does not identify a clear, actionable constraint — email info@schneideraxiom.org for a full refund. If it delivers what it describes — deploy it with one portfolio company before the next operating plan review and evaluate what the structural finding changes about the support design. Schedule a Coffee with Larry call — free, 15 minutes — to discuss the portfolio deployment structure before initiating the partnership process.
"I am not sure whether CAS or CAE is right for the platform team."
If the platform team's primary support engagement is with Series A and Series B stage companies where the constraint operates at the operational or organizational level — CAS. If the platform team regularly works with growth-stage companies or portfolio companies approaching IPO or large strategic transactions where the constraint needs to hold authority at the board and governance level — CAE. Lawrence M. Schneider will tell you directly which credential fits the platform team's current portfolio composition. No sales conversation. Just a direct answer.
Pricing and Portfolio Deployment Structure
Individual analysis — $89
Groups of 10 to 49 — $79 per person
Groups of 50 or more — $69 per person
All venture capital portfolio deployments begin with a coordination call with Lawrence M. Schneider before any portfolio-wide deployment is initiated. Contact SAI directly at info@schneideraxiom.org to schedule the partnership conversation.
If within 72 hours of report delivery the individual analysis does not identify a clear, actionable constraint — email info@schneideraxiom.org for a full refund. After 72 hours refunds are no longer available. Portfolio deployment pricing is non-refundable once the platform team has approved and the deployment has been initiated.
For complete pricing details — see our Pricing and Guarantee page →
How to Get Started
Complete the $89 analysis on your own organization first. Review the written report. Then schedule the portfolio deployment conversation with Lawrence M. Schneider before the next post-close operating plan review.
Complete the $89 Diagnostic on Your Own Organization First → Schedule a Portfolio Deployment Conversation with SAI → Schedule Coffee with Larry — Free, 15 Minutes, No Agenda. →
Frequently Asked Questions
How does the portfolio deployment differ from individual founder enrollment?
Individual founders can complete the $89 analysis independently at any time. The venture capital portfolio deployment is structured differently — the platform team integrates the diagnostic as a standard post-close onboarding component, the platform team receives the aggregated portfolio summary before the operating plan is approved, and the structural finding is used to calibrate support deployment priorities and operating plan design for each specific portfolio company. The founding team receives the same written report either way. The platform team receives the aggregated intelligence that changes what every support function is deployed against.
What does the aggregated portfolio summary show the platform team?
The summary shows the distribution of governing constraints across all seven categories for the full participating portfolio — which constraint categories are most prevalent, which portfolio segments are most commonly governed by which constraint types, and what the structural data suggests about the support deployment priorities that will produce the highest-leverage performance improvement across the portfolio. For a platform team preparing the post-close support plan, the summary tells them which platform functions are most structurally relevant to the constraints actually governing the portfolio — rather than the performance problems the founding teams described in the post-close onboarding.
Can the diagnostic be deployed at multiple stages of the portfolio company lifecycle?
Yes — and for platform teams managing portfolio companies across multiple funding stages, the diagnostic produces different structural value at different stages. At Series A it identifies the governing constraint before the first post-close operating plan is approved. At Series B it identifies whether the constraint that governed Series A performance has been addressed or whether a new constraint category has emerged at the scale the Series B capital is designed to fund. At growth stage it identifies the structural constraint governing the performance gap between the company's current metrics and the benchmark the next institutional event requires. Contact SAI to discuss the multi-stage deployment structure for your portfolio composition.
How does the platform team use the diagnostic finding in the board conversation?
The diagnostic finding is presented at the board as the structural context for the operating plan — not as a replacement for the financial and operational analysis the board meeting includes. A founding team that arrives at a board meeting with a written structural finding, a documented intervention, and a measurable performance improvement is presenting a business narrative with the structural precision that distinguishes a managed constraint from a managed symptom. The board conversation shifts from explaining why the plan missed to presenting evidence that the governing constraint was identified and addressed. That shift changes the quality of the board conversation and the confidence of the performance projections in the operating plan.
What is the guarantee on the $89 analysis?
Full refund if within 72 hours of report delivery the analysis does not identify a clear, actionable governing constraint. Email info@schneideraxiom.org. No questions asked. After 72 hours refunds are no longer available. Portfolio deployment pricing is non-refundable once the platform team has approved and the deployment has been initiated.
The investment thesis was right. The team is strong. The market opportunity is real. And the portfolio company is underperforming the model — not dramatically, but consistently, in a pattern that has persisted across consecutive QBR cycles with accurate situational explanations and no structural cause.
The $89 analysis names the structural cause in 72 hours — before the next operating plan is approved, before the next support deployment is designed against the most visible performance symptom, and before another QBR produces the same performance gap with a different quarter's explanation around it. Name the constraint before the operating plan. Design the support around what you find. That is the difference between a platform team that provides excellent support inside performance gaps — and one that changes what the support produces by addressing the structural cause before the symptom management begins.
Strengthen the individual.
Strengthen the family.
Strengthen the company.
Strengthen America.